Search results
Xyphos and Poseida to develop allogeneic cell therapies for cancer
Pharmaceutical Technology via Yahoo Finance· 3 hours agoPoseida focuses on progressing cell and gene therapies that have the potential to cure certain...
Replay wins IND clearance for PRAME T cell cancer therapy
Pharmaceutical Technology via Yahoo Finance· 22 hours agoGenome writing company Replay Bio has had its investigational new drug (IND) application cleared by...
New technique improves T cell-based immunotherapies for solid tumors
Medical Xpress· 18 hours agoScientists from Scripps Research have enhanced an existing immunotherapy by removing the sugar coating surrounding solid tumors—such as in melanoma, breast, and prostate cancer—so T ...
Astellas and Poseida join forces for cancer cell therapy By Investing.com
Investing.com· 11 hours ago(TSE: 4503) and Poseida Therapeutics, Inc. (NASDAQ: PSTX) have entered a research collaboration and...
TIME100 Health: Stuart Orkin
Time via AOL· 53 minutes agoStuart Orkin didn’t set out to develop a historic treatment for sickle cell disease 45 years ago when he decided to study how blood cells formed. He...
Revolutionizing Cancer Treatment: Key to Prolonging CAR T Cell Life Uncovered
SciTechDaily· 2 days agoFOXO1 is required for T cell memory and is linked to longer-lasting clinical outcomes in CAR T cell ...
TIME100 Health: Georg Schett
Time Magazine· 53 minutes agoIn recent years, the new immune-based therapy CAR T has dramatically improved outcomes for patients with certain blood cancers that involve B cells, like...
... Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic...
FOX21 Colorado Springs· 12 hours agoPoseida is advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases.
Cell and gene therapy companies trip at scalability hurdle
Pharmaceutical Technology via Yahoo Finance· 3 days agoSince then, major strides have been made in the cell therapy space. The first chimeric antigen...
Astellas hitches a ride in Poseida's convertible for $50M cell therapy collaboration
FierceBiotech· 20 hours agoPoseida would also receive royalties on future sales. Poseida will combine its allogeneic CAR-T...
